Clinical Trial

EGb 761 in the Syndrome of MCI With Concomitant CVD

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2022 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-08-20; most recent amendment 2022-11-14.
Status change: Not Yet Recruiting → Recruiting 2021-03-02
Trial Details
NCT Number NCT04525144
Lead Sponsor National Neuroscience Institute
Collaborators: Dr. Willmar Schwabe GmbH & Co. KG
Conditions Mild Cognitive Impairment, Cerebrovascular Disease
Enrollment 134 participants
Start Date 2020-10-26
Primary Completion 2025-12 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2022-11-17